Clinical and Translational Oncology

, Volume 9, Issue 12, pp 767–776 | Cite as

Natural products as leads to anticancer drugs

Educational Series

Abstract

Throughout history, natural products have afforded a rich source of compounds that have found many applications in the fields of medicine, pharmacy and biology. Within the sphere of cancer, a number of important new commercialised drugs have been obtained from natural sources, by structural modification of natural compounds, or by the synthesis of new compounds, designed following a natural compound as model. The search for improved cytotoxic agents continues to be an important line in the discovery of modern anticancer drugs. The huge structural diversity of natural compounds and their bioactivity potential have meant that several products isolated from plants, marine flora and microorganisms can serve as “lead” compounds for improvement of their therapeutic potential by molecular modification. Additionally, semisynthesis processes of new compounds, obtained by molecular modification of the functional groups of lead compounds, are able to generate structural analogues with greater pharmacological activity and with fewer side effects. These processes, complemented with high-throughput screening protocols, combinatorial chemistry, computational chemistry and bioinformatics are able to afford compounds that are far more efficient than those currently used in clinical practice. Combinatorial biosynthesis is also applied for the modification of natural microbial products. Likewise, advances in genomics and the advent of biotechnology have improved both the discovery and production of new natural compounds.

Key words

Natural lead compound Anticancer Camptothecin Podophyllotoxin Taxol Vinblastine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70:461–477PubMedGoogle Scholar
  2. 2.
    Wilson RM, Danishefsky SJ (2006) Small molecule natural products in the discovery of therapeutic agents: the synthesis connection. J Org Chem 71:8329–8351PubMedGoogle Scholar
  3. 3.
    Wilson RM, Danishefsky SJ (2007) Applications of total synthesis toward the discovery of clinically useful anticancer agents. Chem Soc Rev 36:1207–1226PubMedGoogle Scholar
  4. 4.
    Mukherjee AK, Basu S, Sarkat N, Ghosh AC (2001) Advances in cancer therapy with plant based natural products. Curr Med Chem 8:1467–1486PubMedGoogle Scholar
  5. 5.
    Lee KH (1999) Novel antitumor agents from higher plants. Med Res Rev 19:569–596PubMedGoogle Scholar
  6. 6.
    Paterson I, Anderson EA (2005) The renaissance of natural products as drug candidates. Science 310:451–453PubMedGoogle Scholar
  7. 7.
    Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4:206–220PubMedGoogle Scholar
  8. 8.
    Lee K-H (2004) Current developments in discovery and design of new drug candidates from plant natural. J Nat Prod 67:273–283PubMedGoogle Scholar
  9. 9.
    Butler MS (2005) Natural products to drugs: natural products derived compounds in clinical trials. Nat Prod Rep 22:162–195PubMedGoogle Scholar
  10. 10.
    Butler MS (2004) The role of the natural product chemistry in drug discovery. J Nat Prod 67:2141–2153PubMedGoogle Scholar
  11. 11.
    Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4:206–220PubMedGoogle Scholar
  12. 12.
    Newman DJ, Cragg GM (2004) Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod 67:1216–1238PubMedGoogle Scholar
  13. 13.
    Hamann MT, Hill R, Roggo S (2007) Marine natural products. Key advances to the practical application of this resource in drug development. Chimia 61:313–321Google Scholar
  14. 14.
    Simmons TL, Andrianasolo E, McPhail K et al (2005) Marine natural products as anticancer drugs. Mol Cancer Ther 4:333–342PubMedGoogle Scholar
  15. 15.
    Marris E (2006) Marine natural products: drugs from the deep. Nature 443:904–905PubMedGoogle Scholar
  16. 16.
    Schwartsmann G, Brondani da Rocha A, Mattei J, Martins Lopes R (2003) Marine-derived anticancer agents in clinical trials. Expert Opin Investig Drugs 12:1367–1383PubMedGoogle Scholar
  17. 17.
    Blunt JW, Copp BR, Hu VP et al (2007) Marine natural products. Nat Prod Rep 24:31–86PubMedGoogle Scholar
  18. 18.
    Blunt JW, Copp BR, Munro MHG et al (2006) Marine natural product. Nat Prod Rep 23:26–78PubMedGoogle Scholar
  19. 19.
    Morris JC, Nicholas GM, Phillips AJ (2007) Marine natural products: synthetic aspects. Nat Prod Rep 24:87–108PubMedGoogle Scholar
  20. 20.
    Newman DJ, Cragg GM, Sanader KM (2003) Natural products as sources of new drugs over the period 1981–2002. J Nat Prod 66:1022–1037PubMedGoogle Scholar
  21. 21.
    Glaser KB (2007) HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74:659–671PubMedGoogle Scholar
  22. 22.
    Bayes M, Rabasseda X, Prous JR (2007) Gateways to clinical trials. Methods Find Exp Clin Pharmacol 29:303–311PubMedGoogle Scholar
  23. 23.
    Mosley CA, Liotta DC, Snyder JP (2007) Highly active anticancer curcumin analogues. Adv Exp Med Biol 595:77–103PubMedGoogle Scholar
  24. 24.
    Youssef D, Nichols CE, Cameron TS et al (2007) Design, synthesis, and cytostatic activity of novel cyclic curcumin analogues. Bioorg Med Chem Lett 17:5624–5629PubMedGoogle Scholar
  25. 25.
    Johnson JJ, Mukhtar H (2007) Curcumin for chemoprevention of colon cancer. Cancer Lett 255:170–181PubMedGoogle Scholar
  26. 26.
    Cao J, Liu T, Jia L et al (2007) Curcumin induces apoptosis through mitochondrial hyperpolarization and mtDNA damage in human hepatoma G2 cells. Free Radic Biol Med 43:968–975PubMedGoogle Scholar
  27. 27.
    Shishodia S, Chaturvedi MM, Aggarwal BB (2007) Role of curcumin in cancer therapy. Curr Prob Cancer 31:243–305Google Scholar
  28. 28.
    Clardy J (2004) Lessons from natural molecules. Nature 432:829–837PubMedGoogle Scholar
  29. 29.
    Hill RA, Sutherland A (2007) Hot off the press. Nat Prod Rep 24:14–17Google Scholar
  30. 30.
    Amagata T, Minoura K, Numata A (2006) Gymnastatins F-H, cytostatic metabolites from the sponge-derived fungus Gymnascella dankaliensis. J Nat Prod 86:1384–1388Google Scholar
  31. 31.
    Ge HM, Xu C, Wang XT et al (2006) Hopeanol: a potent cytotoxin with a novel skeleton from Hopea exalata. Eur J Org Chem 71:5551–5554Google Scholar
  32. 32.
    Mentel M, Breinbauer R (2007) Combinatorial solid-phase natural product chemistry. Topics Curr Chem 278:209–241Google Scholar
  33. 33.
    Füllbeck M, Michalsky E, Dunkel M, Preissner R (2006) Natural products: sources and data bases. Nat Prod Rep 23:347–356PubMedGoogle Scholar
  34. 34.
    Kingston DGI, Newman DJ (2005) The search for novel drug leads for predominately antitumor therapies by utilizing mother nature’s pharmacophoric libraries. Curr Opin Drug Discov Dev 8:207–227Google Scholar
  35. 35.
    Baltz R (2006) Combinatorial biosynthesis of novel antibiotics and other secondary metabolites in actinomycetes. SIM News 56:148–158Google Scholar
  36. 36.
    Nisbet LJ, Moore M (1997) Will natural products remain an important source of drug research for the future? Curr Opin Biotechnol 8: 708–712PubMedGoogle Scholar
  37. 37.
    Ayres DC, Loike JD (1990) Lignans. Chemical, biological and clinical properties. Cambridge University Press, CambridgeGoogle Scholar
  38. 38.
    Harwelln JL, Schrecker AW (1951) Components of podophyllin. V. The constitution of podophyllotoxin. J Am Chem Soc 73:2909–2916Google Scholar
  39. 39.
    Beutner KR (1996) Podophyllotoxin in the treatment of genital warts. Curr Probl Dermatol 24:227–232PubMedGoogle Scholar
  40. 40.
    Sudo K, Konno K, Shigeta S, Yokota T (1998) Inhibitory effects of podophyllotoxin derivatives on herpes simplex virus replication. Antivir Chem Chemother 9:263–267PubMedGoogle Scholar
  41. 41.
    Leander K, Rosen B (1988) Medicinal used for podophyllotoxin. US patent 4,788,216Google Scholar
  42. 42.
    Ahlmen M, Ahlmen J, Svalander C, Bucht H (1987) Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin Rheumatol 6:27–38PubMedGoogle Scholar
  43. 43.
    Pugh NI, Khan I, Moraes RM, Pasco D (2001) Podophyllotoxin lignans enhance IL-1E but suppress TNF-a mRNA expression in LPS-treated monocytes. Immunopharmacol Immunotoxicol 23:83–95PubMedGoogle Scholar
  44. 44.
    Subrahmanyam D, Renuka B, Rao CV et al (1998) Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents. Bioorg Med Chem Lett 8:1391–1396PubMedGoogle Scholar
  45. 45.
    Utsugi T, Shibata J, Sugimoto Y et al (1996) Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Cancer Res 56:2809–2814PubMedGoogle Scholar
  46. 46.
    Fisher RI, Gaynor ER, Dahlberg S et al (1994) A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate-or high-grade non-Hodgkin’s lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 5[Suppl 2]:91–95PubMedGoogle Scholar
  47. 47.
    Damayanthi Y, Lown JW (1998) Podophyllotoxins: current status and recent developments. Curr Med Chem 5:205–252PubMedGoogle Scholar
  48. 48.
    Imbert TF (1998) Discovery of podophyllotoxins. Biochimie 80:207–222PubMedGoogle Scholar
  49. 49.
    Buss AD, Waigh RD (1995) In: Wolff ME (ed.) Natural products as leads for new pharmaceuticals. John Wiley & Sons Inc, New York, Chapter 24Google Scholar
  50. 50.
    Gordaliza M, García PA, Miguel del Corral JM et al (2004) Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. Toxicon 44:441–459PubMedGoogle Scholar
  51. 51.
    Gordaliza M, Castro A, Miguel del Corral JM, San Feliciano A (2000) Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Design 6:1811–1839Google Scholar
  52. 52.
    Gordaliza M, Miguel del Corral JM, Castro MA et al (1995) Synthesis and evaluation of pyrazolignans. A new class of cytotoxic agents. Bioorg Med Chem 3:1203–1210PubMedGoogle Scholar
  53. 53.
    Von Wartburg A, Stähelin H (1993) Etoposide. In: Lednicer D (ed.) Chronicles of drug discovery. American Chemical Society, Washington DC, pp 349–380Google Scholar
  54. 54.
    Fleming RA, Miller AA, Steward CF (1989) Etoposide: an update. Clin Pharm 8:274–293PubMedGoogle Scholar
  55. 55.
    Meresse P, Dechaux E, Monneret C, Bertounesque E (2004) Etoposide: discovery and medicinal chemistry. Curr Med Chem 11: 2443–2466PubMedGoogle Scholar
  56. 56.
    Stahelin H, Von Wartburg A (1989) From podophyllotoxin glucoside to etoposide. Progress Drug Res 33:169–266Google Scholar
  57. 57.
    Srivastava V, Negi AS, Kumaar JK et al (2005) Plant-based anticancer molecules: a chemical and biological profile of some important leads. Bioorg Med Chem 13:5892–5908PubMedGoogle Scholar
  58. 58.
    Jardin I (1980) Podophyllotoxins. In: Cassady JM, Douros JD (eds) Anticancer agents based on natural models. Academic Press, New York, pp 319–351Google Scholar
  59. 59.
    Gertsch J, Meier S, Tschopp N, Altmann K-H (2007) New tubulin inhibitors from plants a critical assessment. Chimia 61:368–372Google Scholar
  60. 60.
    Hait WN, Rubin E, Alli E, Goodin S (2007) Tubulin targeting agents. Update Cancer Therapeutics 2:1–18Google Scholar
  61. 61.
    Jordan MA, Wilson L (2004) Microtubules as target for anticancer drugs. Nat Rev Cancer 4: 253–265PubMedGoogle Scholar
  62. 62.
    Massanet GM, Pando E, Rodríguez-Luis F, Zubia E (1989) Lignans: a review. Fitoterapia 60: 3–35Google Scholar
  63. 63.
    Row R (1978) Chemistry of lignans. Andhra University Press, Waltair, IndiaGoogle Scholar
  64. 64.
    Ward RS (1997) Lignans, neolignans, and related compounds. Nat Prod Rep 14:43–74Google Scholar
  65. 65.
    Whiting DA (1990) Lignans, neolignans, and related compounds. Nat Prod Rep 7:349–364Google Scholar
  66. 66.
    Canel C, Moraes RM, Dayan FE, Ferreira D (2000) Molecules of interest: podophyllotoxin. Phytochemistry 54:115–120PubMedGoogle Scholar
  67. 67.
    Botta B, Delle Monache G, Misiti D et al (2001) Aryltetralin lignans: chemistry, pharmacology and biotransformations. Curr Med Chem 8: 1363–1381PubMedGoogle Scholar
  68. 68.
    Petersen M, Alfermann AW (2001) The production of cytotoxic lignans by plant cell cultures. Appl Microbiol Biotechnol 55:135–142PubMedGoogle Scholar
  69. 69.
    Liu YQ, Yang L, Tian X (2007) Podophyllotoxin: current perspectives. Curr Bioactive Compounds 3:37–66Google Scholar
  70. 70.
    You Y (2005) Podophyllotoxin derivatives: current synthetic approaches for new anticancer agents. Curr Pharm Design 11:1695–1717Google Scholar
  71. 71.
    Malonne H, Atassi G (1997) DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anti-Cancer Drugs 8:811–822PubMedGoogle Scholar
  72. 72.
    Redkar RG, Jolly CI (2003) Natural products as anticancer agents. Indian Drugs 40:619–626Google Scholar
  73. 73.
    Bohlin L, Rosén B (1996) Podophyllotoxin derivatives: drug discovery and development. Drug Discov Today 1:343–351Google Scholar
  74. 74.
    Kuo-Hsiung L (1999) Novel antitumor agents from higher plants. Med Res Rev 19:569–596Google Scholar
  75. 75.
    Gordaliza M, Castro MA, García-Grávalos MD et al (1994) Antineoplastic and antiviral activities of podophyllotoxin related lignans. Arch Pharm (Weinheim) 327:175–179Google Scholar
  76. 76.
    Gao R, Tian X, Zhang X (2000) A brief review on podophyllotoxin analogues. Chin J Pest Sci 2:1–6Google Scholar
  77. 77.
    Zhu CG, Yang J, Li DZ (2004) Advances in antineoplasm drug-podophyllotoxin and its derivatives. Drug Evaluat 1:306–309Google Scholar
  78. 78.
    Gordaliza M, Castro MA, Miguel del Corral JM et al (2000) Synthesis and antineoplastic activity of cyclolignan aldehydes. Eur J Med Chem 35:691–698PubMedGoogle Scholar
  79. 79.
    Gordaliza M, Miguel del Corral JM, Castro MA et al (2001) Cytotoxic cyclolignans related to podophyllotoxin. Farmaco 56:297–304PubMedGoogle Scholar
  80. 80.
    Castro MA, Miguel del Corral JM, Gordaliza M et al (2004) Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin. J Med Chem 47:1214–1222PubMedGoogle Scholar
  81. 81.
    Kamal A, Gayatri NL, Reddy DR et al (2005) Synthesis and biological evaluation of new 4β-anilino-and 4β-imido-substituted podophyllotoxin congeners. Bioorg Med Chem 13:6218–6225PubMedGoogle Scholar
  82. 82.
    Zhu XK, Guan J, Tachibana Y et al (1999) Antitumor agents. 194. Synthesis and biological evaluations of 4β-mono-,-di-, and-trisubstituted aniline-4′-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles. J Med Chem 42:2441–2446PubMedGoogle Scholar
  83. 83.
    Lee CC, Huang TS (2001) A novel topoisomerase II poison GL331 preferentially induces DNA cleavage at (C/G) T sites and cause telomere DNA damage. Acta Pharm Res 18:846–851Google Scholar
  84. 84.
    Suzuki S, Sakakibara N, Umezawa T, Shimada M (2002) Survey and enzymatic formation of lignans of Anthriscus sylvestris. J Wood Sci 48: 536–541Google Scholar
  85. 85.
    You JZ, Chen YZ (2000) Two new methods for synthesis of 4?-amino-4-deoxypodophyllotoxin and 4?-amino-4′-demethyl-4-deoxypodophyllotoxin. Chem J Chin 21:1064–1066Google Scholar
  86. 86.
    Tratrat C, Giorgi-Renault S, Husson HP (2002) A multicomponent reaction for the one-pot synthesis of 4-aza-2,3-didehydropodophyllotoxin and derivatives. Org Lett 4:3187–3189PubMedGoogle Scholar
  87. 87.
    Zhao C, Nagatsu A, Hatano K et al (2003) New lignan glycosides from Chinese medicinal plant, Sinopodophillum emodi. Chem Pharm Bull 51:255–261PubMedGoogle Scholar
  88. 88.
    Zhao CQ, Huang J, Nagatsu A, Ogihara Y (2001) Two new podophyllotoxin glucosides from Sinopodophyllum emodi (Wall.) Ying. Chem Pharm Bull 49:773–775PubMedGoogle Scholar
  89. 89.
    Gu JQ, Park EJ, Totura S et al (2002) Constituents of the twigs of Hernandia ovigera that inhibit the transformation of JB6 murine epidermal cells. J Nat Prod 65:1065–1068PubMedGoogle Scholar
  90. 90.
    Bathini Y, Scholte A, Kelly S et al (1999) New podophyllotoxin derivatives as potential anticancer agents: Synthesis and cytotoxicity of 4β-O-propenylpodophyllotoxin ethers. Synth Commun 29:379–385Google Scholar
  91. 91.
    Hitotsuyanagi Y, Fukuyo M, Tsuda K et al (2000) 4-Aza-2,3-dehydro-4-deoxypodophyllotoxins: simple aza-podophyllotoxin analogues possessing potent cytotoxicity. Bioorg Med Chem Lett 10:315–317PubMedGoogle Scholar
  92. 92.
    Magedov IV, Manpadi M, Rozhkova E et al (2007) Structural simplification of bioactive natural products with multicomponent synthesis: dihydropyridopyrazole analogues of podophyllotoxin. Bioorg Med Chem Lett 17:1381–1385PubMedGoogle Scholar
  93. 93.
    Magedov IV, Manpadi M, Van Slambrouck S et al (2007) Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by one-step multicomponent synthesis. J Med Chem 50:5183–5192PubMedGoogle Scholar
  94. 94.
    Li S-J, Zhong J-H, Wang Y-G (2006) Synthesis of new chiral N-heterocyclic carbenes from naturally occurring podophyllotoxin and their application to asymmetric allylic alkylation. Tetrahedron: Asymmetry 17:1650–1654Google Scholar
  95. 95.
    Jin Y, Chen S-W, Tian X (2006) Synthesis and biological evaluation of new spin-labeled derivatives of podophyllotoxin. Bioorg Med Chem 14:3062–3068PubMedGoogle Scholar
  96. 96.
    Lee N-J, Jeong I-C, Cho M-Y et al (2006) Synthesis and in vitro antitumor activity of phthalimide polymers containing podophyllotoxin. Eur Polymer J 42:3352–3359Google Scholar
  97. 97.
    Wall ME, Wani MC, Cook CE et al (1966) Plants antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukaemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888–3890Google Scholar
  98. 98.
    Chavan SP, Pathak AB, Kalkote UR (2007) Total synthesis of (+)-camptothecin via an intramolecular palladium-catalyzed cyclization strategy. SynLett 2635Google Scholar
  99. 99.
    Hartmann JT, Lipp HP (2006) Camptothecin and podophyllotoxin derivatives: Inhibitor of topoisomerase I and II — mechanism of action, pharmacokinetics and toxicity profile. Drug Safety 29:209–230PubMedGoogle Scholar
  100. 100.
    Wall ME (1998) Camptothecin and taxol: discovery to clinic. Med Res Rev 18:299–314PubMedGoogle Scholar
  101. 101.
    Cragg GM, Newman DJ (2005) Plants as a source of anti-cancer agents. J Ethnopharmacol 100:72–79PubMedGoogle Scholar
  102. 102.
    Hisiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 88:3888–3890Google Scholar
  103. 103.
    Braña MF, Sanchez-Migallón A (2006) Anticancer drug discovery and pharmaceutical chemistry: a history. Clin Transl Oncol 8:717–728PubMedGoogle Scholar
  104. 104.
    Rothenberg ML (1997) Topoisomerase I inhibitors: review and update. Ann Oncol 8:837–855PubMedGoogle Scholar
  105. 105.
    Kingsbury WD, Boehm JC, Jakas DR (1991) Synthesis of water-soluble (aminoalkyl) camptothecin analogs: inhibition of topoisomerase I and antitumor activity. J Med Chem 34:98–107PubMedGoogle Scholar
  106. 106.
    Sawada S, Okajima S, Piyama R et al (1991) Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate linked, water soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem Pharm Bull 39:1446–1450PubMedGoogle Scholar
  107. 107.
    Potmesil M (1994) Camptothecins: from bench research to hospital wards. Cancer Res 54:1431–1439PubMedGoogle Scholar
  108. 108.
    García Carbonero R, Supko JG (2002) Current perspectives on the clinical experience, pharmacology and continued development of the camptothecins. Clin Cancer Res 8:641–661PubMedGoogle Scholar
  109. 109.
    Dennis MJ, Beijnene JH, Grochow LB, van Wamerdam LJ (1997) An overview of the clinical pharmacology of topotecan. Semin Oncol 24[1 Suppl 5]:S5-12–S5-18Google Scholar
  110. 110.
    O’Reilly S (1999) Topotecan: what dose, what schedule, what route? Clin Cancer Res 5:3–5PubMedGoogle Scholar
  111. 111.
    Shah C, Ready N, Perry M et al (2007) A multicenter phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung Cancer 57:84–88PubMedGoogle Scholar
  112. 112.
    Nelson R (2007) Topotecan more effective than supportive care. Lancet Oncol 8:13PubMedGoogle Scholar
  113. 113.
    Spannuth WA, Leath CA, Huh WK et al (2007) A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. Gynecol Oncol 104: 591–595PubMedGoogle Scholar
  114. 114.
    Gould P (2006) Topotecan adds no benefit in advanced ovarian cancer. Lancet Oncol 7:799Google Scholar
  115. 115.
    Ormrod D, Spencer CM (2002) Topotecan in the treatment of recurrent ovarian cancer. Oncologist 7[Suppl 5]:3–18Google Scholar
  116. 116.
    Herben VMM, Ten Bokked Huinink WW, Beijnen JH (1996) Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 31:85–102PubMedGoogle Scholar
  117. 117.
    Cersisimo RJ (1998) Irinotecan: a new antineoplastic agent for the management of colorectal cancer. Ann Pharmacother 32:1324–1333Google Scholar
  118. 118.
    Erlichman C, Sargent DJ (2004) new treatment options for colorectal cancer. N Engl J Med 351:391PubMedGoogle Scholar
  119. 119.
    Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905PubMedGoogle Scholar
  120. 120.
    Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335PubMedGoogle Scholar
  121. 121.
    Limonti A, Satta F, Pavese I et al (2003) Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. Ann Oncol 14:805–806Google Scholar
  122. 122.
    Wasserman E, Cuvier C, Lokiec F et al (1999) Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol 17:1751–1759PubMedGoogle Scholar
  123. 123.
    Johnson IS (1968) Historical background of Vinca alkaloids research and areas of future interest. Cancer Chemother Rep 52:455–461PubMedGoogle Scholar
  124. 124.
    Samuelsson G (1999) Drugs of natural origin, 4th Edn. Swedish Pharmaceutical Press, SwedenGoogle Scholar
  125. 125.
    Effert T, Li PCH, Konkimalla VSB (2007) From traditional Chinese medicine to cancer therapy. Trends Molec Med 13:353–361Google Scholar
  126. 126.
    Xie J, Tan F (2007) Advances in studies on antitumor drugs originated from plant. Chin Trad Herbal Drugs 38:285–289Google Scholar
  127. 127.
    El-Sayed M, Velporte R (2007) Catharantus terpenoids indole alkaloids: biosynthesis and regulation. Phytochem Rev 6:277–305Google Scholar
  128. 128.
    Levêque D, Jehl F (2007) Molecular pharmacokinetics of Catharanthus (Vinca) alkaloids. J Clin Pharm 47:579–588Google Scholar
  129. 129.
    Himes RH (1991) Interactions of Catharantus (Vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 51:257–267PubMedGoogle Scholar
  130. 130.
    Ding YF, Bao XD, An LJ (2005) Progress research of antitumor agents vinblastine analogues. Chin J Pharm 26:424–428Google Scholar
  131. 131.
    You J, Wan F, de Cui F et al (2007) Preparation and characteristic of vinorelbine bitartrate-loaded solid lipid nanoparticles. Int J Pharm 343:270–276PubMedGoogle Scholar
  132. 132.
    Mano M (2006) Vinorelbine in the management of breast cancer: new perspectives, revived role in the era of targeted therapy. Cancer Treat Rev 32:106–118PubMedGoogle Scholar
  133. 133.
    Goodman J, de Walsh V (2001) The story of taxol: nature and politics in the pursuit of an anticancer drug. Cambridge University Press, CambridgeGoogle Scholar
  134. 134.
    Kingston DGI, Newman DJ (2007) Taxoids: cancer-fighting compound from nature. Curr Opin Drug Discov Dev 10:130–144Google Scholar
  135. 135.
    Yazdani D, Shahnazi S, Rezazadeh Sh, Pirali Hamadani M (2005) Review on yew tree (Taxus spp). J Medicinal Plants 4:1–8Google Scholar
  136. 136.
    Kingston DGI (2001) Taxol, a molecule for all seasons. Chem Commun 867–880Google Scholar
  137. 137.
    Nicolau KC, Yang Z, et al (1994) Total synthesis of taxol. Nature 367:630–634Google Scholar
  138. 138.
    Danishefsky SJ, Masters JJ, Young WB et al (1996) Total synthesis of baccatin III and taxol. J Am Chem Soc 118:2843–2859Google Scholar
  139. 139.
    Borah JC, Boruwa J, Barua NC (2007) Synthesis of the C-13 side-chain of taxol. Curr Org Syn 4:175–199Google Scholar
  140. 140.
    Guo BH, Kai GY, Jin HB, Tang KX (2006) Taxol synthesis. Afr J Biotechnol 5:15–20Google Scholar
  141. 141.
    Shi Q-W, Kiyota H (2005) New natural taxane diterpenoids from Taxus species since 1999. Chem Biodivers 2:1597–1623PubMedGoogle Scholar
  142. 142.
    Nakagawa-Goto K, Yamada K, Nakamura S et al (2007) Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant — taxoid conjugates as novel cytotoxic agents. Bioorg Med Chem Lett 17:5204–5209PubMedGoogle Scholar
  143. 143.
    Ferjancic Z, Matovic R, Cekovic Z et al (2006) Synthesis, biology, and modeling of a C-4 carbonyl C,D-seco-taxoid. Tetrahedron 62:8503–8514Google Scholar
  144. 144.
    Kuznetsova L, Chen J, Sun L et al (2006) Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents. Bioorg Med Chem Lett 16:974–977PubMedGoogle Scholar
  145. 145.
    Kingston DGI (2007) The shape of things to come: structural and synthetic studies of taxol and related compounds. Phytochemistry 68:1844–1854PubMedGoogle Scholar
  146. 146.
    Sengupta S (2006) Drug target interaction of tubulin-binding drugs in cancer therapy. Exp Rev Anticancer Ther 6:1433–1447Google Scholar
  147. 147.
    Bergstralh DT, Ting JP-Y (2006) Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat Rev 32:166–179PubMedGoogle Scholar
  148. 148.
    Altmann K-H, Gertsch J (2007) Anticancer drugs from nature — natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Rep 24:327–357PubMedGoogle Scholar
  149. 149.
    Leistner E (2005) Drugs from nature: biology of taxanes. Pharm Unserer Zeit 34:98–103PubMedGoogle Scholar
  150. 150.
    Malonga H, Neault JF, Diamantoglou S, Tajmir-Riahi HA (2005) Taxol anticancer activity and DNA binding. Mini-Rev Med Chem 5:307–311PubMedGoogle Scholar
  151. 151.
    Kingston DGI, Bane S, Snyder JP (2005) The taxol pharmacophore and the T-taxol bridging principle. Cell Cycle 4:279–289PubMedGoogle Scholar
  152. 152.
    Nabholtz J-M, Gligorov J (2005) The role of taxanes in the treatment of breast cancer. Exp Opin Pharmacother 6:1073–1094Google Scholar
  153. 153.
    Dubois J (2006) Recent progress in the development of docetaxel and paclitaxel analogues. Exp Opin Ther Patents 16:1481–1496Google Scholar
  154. 154.
    Fang WS, Lian XT (2005) Recent progress in structure activity relationship and mechanistic studies of taxol analogues. Mini-Rev Med Chem 5:1–12PubMedGoogle Scholar
  155. 155.
    Ojima I, Geney R, Ungureanu IM, Li D (2002) Medicinal chemistry and chemical biology of new generation taxane antitumor agents. IUBMB Life 53:269–274PubMedGoogle Scholar
  156. 156.
    Ojima I, Geng X, Wu X et al (2002) Tumor-specific novel taxoid-monoclonal antibody conjugates. J Med Chem 45:5620–5623PubMedGoogle Scholar
  157. 157.
    Tietze LF, Bell HP, Chandrasekhar S (2003) Natural product hybrids as new leads for drug discovery. Angew Chem Int Ed 42:3996–4028Google Scholar
  158. 158.
    White SJ, Kasman LM, Kelly MM et al (2007) Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2. Free Radic Biol Med 43:1313–1321PubMedGoogle Scholar
  159. 159.
    Busquets S, Ametller E, Fuster G et al (2007) Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett 245:144–148PubMedGoogle Scholar

Copyright information

© Feseo 2007

Authors and Affiliations

  1. 1.Departamento de Química Farmacéutica Facultad de FarmaciaUniversidad de SalamancaSalamancaSpain

Personalised recommendations